Format

Send to

Choose Destination
See comment in PubMed Commons below
Integr Cancer Ther. 2009 Mar;8(1):71-4. doi: 10.1177/1534735408327995. Epub 2009 Jan 15.

Anticancer effects of HESA-A in patients with metastatic colon cancer.

Author information

1
Institute of Cancer Research, Medical Sciences/University of Tehran, Tehran, Iran. swt_f@yahoo.com

Abstract

BACKGROUND:

HESA-A is a natural biological compound of herbal-marine origin. The aim of this study was to investigate the therapeutic effects of HESA-A in patients with metastatic colon cancer.

METHODS:

Fifty consecutive patients with end-stage colon cancer and liver metastasis at the Cancer Research Center of Tehran University of Medical Sciences were studied. Patients received HESA-A 50 mg/kg/d orally in 2 to 3 divided doses for 6 months. The patients were assessed at the start and end of the 1st, 2nd, 4th, 8th, 12th, 16th, 20th, and 26th weeks of the study. The Karnofsky Performance Scale questionnaire was completed for each patient.

RESULTS:

The mean Karnofsky performance score increased from 33.6 +/- 9.8 to 63.3 +/- 11 after 10 weeks of study. No significant hepatic or hematological adverse effects were seen during the study.

CONCLUSION:

It seems that HESA-A is an effective and safe anticancer drug, which can be used in selected patients.

PMID:
19147644
DOI:
10.1177/1534735408327995
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center